| Name | Title | Contact Details |
|---|---|---|
Mike Robinson |
VP of Engineering | Profile |
Xontogeny is a life sciences accelerator that collaborates with entrepreneurs, scientific founders and first-time CEOs to drive the successful development of their technologies to enable new treatment options for patients with serious disease.
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx`s protein engineering technology.
Neuralink is developing the capabilities of the brain through technological augmentation. A "neural lace” would be surgically connected to a human brain and allow a user to interact with a computer without the bandwidth challenges that come with current input methods, including keyboards, mice and trackpads. Neuralink will explore how brain interfaces might alleviate the symptoms of dangerous and chronic medical conditions.
Coventry Health is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ferre Institute is a Binghamton, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.